Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Blood (2018) 132 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2018-99-112447

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Who Are the Type 2 Von Willebrand Disease Patients? Results from Interim Analysis of the French HRQoL Study: Wish-Qol .

Annie Borel-Derlon, MD PhD, Jenny Goudemand, MD PhD, Dominique Desprez, MD, Céline Falaise, Fabienne Genre Volot, MD, Laurent Ardillon, MD, Brigitte Pan-Petesch, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Agnès Veyradier, Sr., MD PhD, Sylvia Von Mackensen

Blood (2018) 132 (Supplement 1): 2468.

https://doi.org/10.1182/blood-2018-99-113289

Published: 2018

Journal Articles

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Luciano Baronciani, PhD, Flora Peyvandi, MD PhD, Anne Goodeve, PhD, Reinhard Schneppenheim, MDPhD, Zahra Badiee, Mohammad-Reza Baghaipour, Javier Battle, Erik Berntorp, MD PhD, Imre Bodó, MD PhD, Ulrich Budde, MD, Andrea Cairo, PhD, Giancarlo Castaman, Laura Crookes, Jeroen C.J. Eikenboom, MD, Peyman Eshghi, MD, Cosimo Ettorre, MD, Jenny Goudemand, MD PhD, Wolf Hassenpflug, Charles Richard Morris Hay, MDFRCP,FRCPath, Hamid Hoorfar, MD, Mehran Karimi, MD, Bijan Keikhaei, Riitta Lassila, MD PR, Frank W.G. Leebeek, MD PhD, Maria Fernanda Lopez Fernandez, Pier Mannuccio Mannucci, MD, Maria Gabriella Mazzucconi, MD, Massimo Morfini, MD, Nikolas Nikšić, Johannes Oldenburg, Florian Oyen, Rafael Parra Lòpez, Ian Peake, PhD, Gholamreza Toogeh, Alberto Tosetto, Marc Trossaert, Sayed Omid Reza Zekavat, MD, Eva M.K. Zetterberg, MD PhD, Augusto B Federici, MD

Blood (2018) 132 (Supplement 1): 1184.

https://doi.org/10.1182/blood-2018-99-114702

Published: 2018

Journal Articles

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Annie Borel-Derlon, MD PhD, Dominique Desprez, MD, Fabienne Volot, MD, Herve Chambost, MD PhD, Sophie Bayard, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Yves Gruel, MD PhD, Agnès Veyradier, Sr., MD PhD, Jenny Goudemand, MD PhD, Sylvia Von Mackensen, PhD

Blood (2017) 130 (Supplement 1): 4866.

https://doi.org/10.1182/blood.V130.Suppl_1.4866.4866

Published: 2017

Journal Articles

Wish-Qol Study - Assessment of Health-Related Quality of Life (HRQoL) and Health-Economic Aspects in Patients with Von Willebrand Disease (VWD) in France: Results of the Women Cohort

Annie Borel-Derlon, MD PhD, Jenny Goudemand, MD PhD, Dominique Desprez, MD, Fabienne Volot, MD, Yves Gruel, MD, Sophie Bayard, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Agnes Veyradier, MD PhD, Edith Fressinaud, MD, Sylvia von Mackensen, PhD

Blood (2016) 128 (22): 1395.

https://doi.org/10.1182/blood.V128.22.1395.1395

Published: 2016

Journal Articles

High-Throughput Genotyping of Haemophilia A and B Using Next-Generation Sequencing Technology in Lille University Hospital

Fanny Lassalle, PharmD, Antoine Rauch, MD PhD, Benedicte Wibaut, MD PhD, Christine Vinciguerra, PharmD, PhD, Mathilde Fretigny, PharmD, PhD, Bertrand Vaast, Valerie Gomanne, Sophie Susen, MD PhD, Jenny Goudemand, MD PhD, Christophe Zawadzki, PharmD, PhD

Blood (2015) 126 (23): 2273.

https://doi.org/10.1182/blood.V126.23.2273.2273

Published: 2015

Journal Articles

Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedures

Antoine Rauch, MD, Eric Van Belle, MD PhD, André Vincentelli, MD PhD, Paulette Legendre, Emmanuelle Jeanpierre, Christopher Hurt, MD, Carlo Banfi, MD, Claudine Caron, Francis Juthier, MD PhD, Ahmed Elkalioubie, MDPhD, Natacha Rousse, MD, Delphine Corseaux, PhD, Christophe Zawadzki, PhD, Giulia Chinetti, PhD, Brigitte Jude, MD PhD, Jenny Goudemand, MD PhD, Bart Staels, Peter J. Lenting, PhD, Sophie Susen, MDPhD

Blood (2014) 124 (21): 474.

https://doi.org/10.1182/blood.V124.21.474.474

Published: 2014

Journal Articles

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Catherine Boyer-Neumann, Annie Borel-Derlon, MD, PhD, Jenny Goudemand, MD, PhD, Ségolène Claeyssens, Pierre-Marie Sie, MD, PhD, Philippe Moreau, Marie-Anne Bertrand, MD, Chantal Rothschild, MD, Benoît Guillet, MD, PhD, Jeanne Yvonne Borg, Catherine Chatelanaz, Wil Stevens, Françoise Bridey, Celine Henriet

Blood (2012) 120 (21): 3375.

https://doi.org/10.1182/blood.V120.21.3375.3375

Published: 2012

Journal Articles

Intracellular Retention, Enhanced Clearance, and Defective FVIII Binding Are Common Features of Von Willebrand Factor D'-D3 Domain Mutations in Patients with Von Willebrand Disease Type 1 From the European Mcmdm-1VWD Study

Reinhard Schneppenheim, MD, PhD, Ulrich Budde, MD, Javier Batlle, MD, Giancarlo Castaman, MD, Jeroen C. J. Eikenboom, MD, PhD, Augusto B. Federici, MD, Jenny Goudemand, MD, PhD, Tobias Obser, Florian Oyen, Francesco Rodeghiero, MD, Sonja Schneppenheim, MD, Ian R. Peake, PhD, Anne C. Goodeve, PhD

Blood (2012) 120 (21): 99.

https://doi.org/10.1182/blood.V120.21.99.99

Published: 2012

Journal Articles

Clinical Use of a Von Willebrand Factor with a Low FVIII Content in Von Willebrand Disease Patients Undergoing Surgical Procedures or Deliveries: Results From 5 Prospective Multicenter Studies

Annie Borel-Derlon, MD, PhD, Augusto B. Federici, MD, Jenny Goudemand, MD, PhD, Catherine Chatelanaz, Celine Henriet, Françoise Bridey

Blood (2011) 118 (21): 383.

https://doi.org/10.1182/blood.V118.21.383.383

Published: 2011

Journal Articles

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Roseline d'Oiron, MD, Virginie Demiguel, MSc, Annie Borel-Derlon, MD, PhD, Ségolène Donadel-Claeyssens, MD, PhD, Jenny Goudemand, MD, PhD, Benoît Guillet, MD, PhD, Yves Gruel, MD, PhD, Valérie Roussel-Robert, MD, Fabienne Volot, MD, Thierry Calvez, MD, MSc

Blood (2011) 118 (21): 1213.

https://doi.org/10.1182/blood.V118.21.1213.1213

Published: 2011

Journal Articles

First Case of Platelet-Type Von Willebrand Disease (PT-VWD) Associated with Type 2B Von Willebrand Disease (2B VWD)

Marie Dreyfus, Celine Desconclois, Corinne Guitton, Marie-Jeanne Baas, Helene Mandard, Pierre Boisseau, Jenny Goudemand, MD, PhD, Claudine Caron, Nathalie Itzhar, Agnes Veyradier, Francois Lanza, PhD, MD, Edith Fressinaud

Blood (2011) 118 (21): 5313.

https://doi.org/10.1182/blood.V118.21.5313.5313

Published: 2011

Journal Articles

Clinical and Prognostic Implications of Low or High Level of Von Willebrand Factor (VWF) In Waldenström Macroglobulinemia (WM) Patients (pts). A Clinicopathological Study on 72 Pts

Bénédicte Hivert, Claudine Caron, Stéphanie Petit, Cécile Charpy, Corinne Fankam-Siaka, Alain Duhamel, Olivier Tournilhac, MD, PhD, Jenny Goudemand, MD, PhD, Pierre Morel

Blood (2010) 116 (21): 2438.

https://doi.org/10.1182/blood.V116.21.2438.2438

Published: 2010

Journal Articles

O -Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.

Peter J. Lenting, PhD, Carina J.M. van Schooten, MSc, Ton Lisman, PhD, Marijke van den Berg, MD, PhD, Jeroen C.J. Eikenboom, MD, PhD, Frank W.G. Leebeek, MD, PhD, Jenny Goudemand, MD, PhD, Edith Fressinaud, MD, PhD, Philip G. de Groot, PhD, Cécile V. Denis, PhD

Blood (2006) 108 (11): 178.

https://doi.org/10.1182/blood.V108.11.178.178

Published: 2006

Journal Articles

Severe Aortic and Mitral Valve Regurgitation Are Associated with von Willebrand Factor Defect.

Sophie Susen, MD, Andre Vincentelli, MD, PhD, Thierry Le Tourneau, MD, PhD, Claudine Caron, Christophe Zawadzki, MD, Alain Prat, MD, Jenny Goudemand, MD, PhD, Brigitte Jude, MD, PhD

Blood (2005) 106 (11): 1790.

https://doi.org/10.1182/blood.V106.11.1790.1790

Published: 2005

Journal Articles

Immune Tolerance with a High Purity Plasma Derived Factor VIII Containing Von Willebrand Factor in Haemophilia A Patients with High Responding Inhibitors.

Benoit Polack, MD, PhD, Philippe Beurrier, MD, Chantal Rothschild, MD, Frédérique Orsini, Albert Faradji, MD, Anne Liennhard, MD, Edith Fressinaud, MD, PhD, Jenny Goudemand, MD

Blood (2004) 104 (11): 3096.

https://doi.org/10.1182/blood.V104.11.3096.3096

Published: 2004

Journal Articles

U.S. Factor XI Patients: Is There a Safer Treatment? Yes - Hemoleven.

Louis M. Aledort, MD, Jenny Goudemand, MD

Blood (2004) 104 (11): 4005.

https://doi.org/10.1182/blood.V104.11.4005.4005

Published: 2004

NARROW

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Who Are the Type 2 Von Willebrand Disease Patients? Results from Interim Analysis of the French HRQoL Study: Wish-Qol .

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Wish-Qol Study - Assessment of Health-Related Quality of Life (HRQoL) and Health-Economic Aspects in Patients with Von Willebrand Disease (VWD) in France: Results of the Women Cohort

High-Throughput Genotyping of Haemophilia A and B Using Next-Generation Sequencing Technology in Lille University Hospital

Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedures

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Intracellular Retention, Enhanced Clearance, and Defective FVIII Binding Are Common Features of Von Willebrand Factor D'-D3 Domain Mutations in Patients with Von Willebrand Disease Type 1 From the European Mcmdm-1VWD Study

Clinical Use of a Von Willebrand Factor with a Low FVIII Content in Von Willebrand Disease Patients Undergoing Surgical Procedures or Deliveries: Results From 5 Prospective Multicenter Studies

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

First Case of Platelet-Type Von Willebrand Disease (PT-VWD) Associated with Type 2B Von Willebrand Disease (2B VWD)

Clinical and Prognostic Implications of Low or High Level of Von Willebrand Factor (VWF) In Waldenström Macroglobulinemia (WM) Patients (pts). A Clinicopathological Study on 72 Pts

O -Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.

Severe Aortic and Mitral Valve Regurgitation Are Associated with von Willebrand Factor Defect.

Immune Tolerance with a High Purity Plasma Derived Factor VIII Containing Von Willebrand Factor in Haemophilia A Patients with High Responding Inhibitors.

U.S. Factor XI Patients: Is There a Safer Treatment? Yes - Hemoleven.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only